Bosutinib safety and management of toxicity in leukemia patients with resistance or intolerance to imatinib and other tyrosine kinase inhibitors-Reference-Cited by-同舟云学术

Bosutinib safety and management of toxicity in leukemia patients with resistance or intolerance to imatinib and other tyrosine kinase inhibitors

Published:2014-02-27 Issue:9 Volume:123 Page:1309-1318
ISSN:0006-4971
Container-title:Blood
language:en
Short-container-title:

Author:

Kantarjian Hagop M.¹,Cortes Jorge E.¹,Kim Dong-Wook²,Khoury H. Jean³,Brümmendorf Tim H.⁴⁵,Porkka Kimmo⁶,Martinelli Giovanni⁷,Durrant Simon⁸,Leip Eric⁹,Kelly Virginia¹⁰,Turnbull Kathleen¹¹,Besson Nadine¹²,Gambacorti-Passerini Carlo¹³

Affiliation:

1. Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX;

2. Department of Hematology, Seoul St. Mary’s Hospital, Seoul, South Korea;

3. Department of Hematology and Medical Oncology, Winship Cancer Institute of Emory University, Atlanta, GA;

4. Hematology, Oncology, and Stem Cell Transplantation, Universitätsklinikum Aachen, Rheinisch-Westfaelische Technische Hochschule Aachen, Aachen, Germany;

5. Hematology, Oncology, and Stem Cell Transplantation, Universitätsklinikum Hamburg-Eppendorf, Hamburg, Germany;

6. Division of Hematology, Helsinki University Central Hospital, Helsinki, Finland;

7. Department of Experimental, Diagnostic and Specialty Medicine, University of Bologna, Bologna, Italy;

8. Bone Marrow Transplant Unit, Royal Brisbane Hospital, Herston, Australia;

9. Oncology Clinical Statistics,

10. Oncology Clinical Research, and

11. Oncology Clinical Development, Pfizer Inc., Cambridge, MA;

12. Pfizer Global Research and Development, Paris, France; and

13. Clinical Research Unit, University of Milano-Bicocca, Monza, Italy

Abstract

Key Points Bosutinib had manageable toxicity and acceptable tolerability, with adverse events distinct from that of other tyrosine kinase inhibitors. Adverse events were primarily characterized by early-onset gastrointestinal events that were low grade, transient, and manageable.

Publisher

American Society of Hematology

Subject

Cell Biology,Hematology,Immunology,Biochemistry

Link

http://ashpublications.org/blood/article-pdf/123/9/1309/1378617/1309.pdf

Reference21 articles.

1. European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013.;Baccarani;Blood,2013

2. National Comprehensive Cancer Network NCCN Clinical Practice Guidelines in Oncology™. Chronic Myelogenous Leukemia. Version 1. 2014. Available at: http://www.nccn.org/professionals/physician_gls/pdf/cml.pdf. Accessed October 3, 2013

3. National Comprehensive Cancer Network NCCN Clinical Practice Guidelines in Oncology™. Acute Lymphoblastic Leukemia. Version 1. 2013. Available at: http://www.nccn.org/professionals/physician_gls/pdf/all.pdf. Accessed October 3, 2013

4. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia.;O’Brien;N Engl J Med,2003

5. Imatinib for newly diagnosed patients with chronic myeloid leukemia: incidence of sustained responses in an intention-to-treat analysis.;de Lavallade;J Clin Oncol,2008

Cited by 121 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Unveiling the nephrotoxic profile of BCR‐ABL tyrosine kinase inhibitors: A real‐world experience in Africa;eJHaem;2024-07-31

2. The FABD domain is critical for the oncogenicity of BCR/ABL in chronic myeloid leukaemia;Cell Communication and Signaling;2024-06-07

3. Targeting oncogenic kinases: Insights on FDA approved tyrosine kinase inhibitors;European Journal of Pharmacology;2024-05

4. Incidence of pleural effusion with dasatinib and the effect of switching therapy to a different TKI in patients with chronic phase CML;Annals of Hematology;2024-04-18

5. Stem cell allografting for chronic Myeloid leukemia in the tyrosine kinase era – forgotten but not gone;Leukemia & Lymphoma;2024-02-09